1589917612572_5ec429193ef97e0004f1060c_logo.png
Timber Pharmaceuticals Announces Pricing of $15 Million Public Offering
November 03, 2021 08:00 ET | Timber Pharmaceuticals
Basking Ridge, NJ, Nov. 03, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire --Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the...
1589917612572_5ec429193ef97e0004f1060c_logo.png
Timber Pharmaceuticals Announces Proposed Public Offering
November 02, 2021 16:31 ET | Timber Pharmaceuticals
Basking Ridge, NJ, Nov. 02, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the...
1589917612572_5ec429193ef97e0004f1060c_logo.png
Timber Pharmaceuticals Reports Positive Top-line Results from Phase 2b CONTROL Study Evaluating TMB-001 in Moderate to Severe Congenital Ichthyosis
October 07, 2021 09:11 ET | Timber Pharmaceuticals
Data demonstrate reduction in targeted and overall severity of CI in patients treated with topical IPEG™ TMB-001 (topical isotretinoin) Company planning for end-of-Phase 2 meeting with FDA in the...
1589917612572_5ec429193ef97e0004f1060c_logo.png
Timber Pharmaceuticals Presents at EADV’s 30th Anniversary Congress
October 01, 2021 08:00 ET | Timber Pharmaceuticals
Basking Ridge, N.J., Oct. 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the...
1589917612572_5ec429193ef97e0004f1060c_logo.png
Timber Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 10, 2021 17:58 ET | Timber Pharmaceuticals
BASKING RIDGE, NJ, Sept. 10, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the...
1589917612572_5ec429193ef97e0004f1060c_logo.png
Timber Pharmaceuticals Announces Last Patient Last Visit in Phase 2b CONTROL Study Evaluating TMB-001 in Moderate to Severe Congenital Ichthyosis
August 24, 2021 08:00 ET | Timber Pharmaceuticals
- Topline results expected to be announced in the fourth quarter of 2021 - - Company preparing for an End-of-Phase 2 meeting with the FDA - Basking Ridge, N.J., Aug. 24, 2021 (GLOBE...
1589917612572_5ec429193ef97e0004f1060c_logo.png
Timber Pharmaceuticals Provides Business Update and Announces Second Quarter 2021 Financial Results
August 10, 2021 08:00 ET | Timber Pharmaceuticals
BASKING RIDGE, NJ, Aug. 10, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the...
1589917612572_5ec429193ef97e0004f1060c_logo.png
Timber Pharmaceuticals Announces Adjournment of Annual Meeting
June 03, 2021 16:05 ET | Timber Pharmaceuticals
Basking Ridge, NJ, June 03, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the...
1589917612572_5ec429193ef97e0004f1060c_logo.png
Timber Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2b CONTROL Study Evaluating TMB-001 in Congenital Ichthyosis
May 26, 2021 16:05 ET | Timber Pharmaceuticals
- Company plans to ask for end-of-Phase 2 meeting with FDA by end of 2021 - Basking Ridge, N.J., May 26, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or...
1589917612572_5ec429193ef97e0004f1060c_logo.png
Timber Pharmaceuticals Provides Business Update and Announces First Quarter 2021 Financial Results
May 11, 2021 16:39 ET | Timber Pharmaceuticals
BASKING RIDGE, NJ, May 11, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the...